Expanded Access for KHK2455

Expanded Access for KHK2455

This is an expanded access program for eligible participants. This program is designed to provide access to KHK2455 in combination with Mogamulizumab prior to the approval by the local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving this investigational therapy based on the individual patients medical history and eligibility criteria.

Inclusion Criteria:

-

Exclusion Criteria:

-